A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy

2015 ◽  
Vol 24 (3) ◽  
pp. 379-382
Author(s):  
Tadahisa Inoue ◽  
Hitoshi Sano ◽  
Takashi Mizushima ◽  
Hirotada Nishie ◽  
Hiroyasu Iwasaki ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Distant Metastases ◽  
Salvage Chemotherapy ◽  
Second Line ◽  
Effective Treatment Option ◽  
Second Line Chemotherapy ◽  
Best Response ◽  
Long Term Effect ◽  
Line Chemotherapy

We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.

scholarly journals Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

1995 ◽  
Vol 34 (2) ◽  
pp. 185-189 ◽  
Author(s):  
M. Bontenbal ◽  
A. S. Th. Planting ◽  
J. Verweij ◽  
R. de Wit ◽  
W. H. J. Kruit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Advanced Breast ◽  
Oral Etoposide ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Dose Oral ◽  
Line Chemotherapy

scholarly journals Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma

Pancreas ◽  
2020 ◽  
Vol 49 (4) ◽  
pp. 529-533 ◽  
Author(s):  
Patrick W. McGarrah ◽  
Konstantinos Leventakos ◽  
Timothy J. Hobday ◽  
Julian R. Molina ◽  
Heidi D. Finnes ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Outcome of Transplant-Eligible Patients with Hodgkin Lymphoma with An Inadequate Response to Second Line Chemotherapy with Gemcitabine, Dexamethasone, Cisplatin (GDP).

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2179-2179
Author(s):  
Tara Seshadri ◽  
Christine Massey ◽  
Noemi Puig ◽  
Armand Keating ◽  
Michael Crump ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Salvage Chemotherapy ◽  
Inadequate Response ◽  
Second Line ◽  
First Line ◽  
Second Line Chemotherapy ◽  
Disease Characteristics ◽  
Mass Size ◽  
Line Chemotherapy

Abstract Introduction: Standard practice for patients (pts) with Hodgkin Lymphoma (HL) who relapse or are refractory to primary therapy is second line chemotherapy followed by an autologous hematopoietic cell transplant (AHCT) in those who demonstrate chemotherapysensitive disease. Management of pts who achieve less than a partial remission (PR) to first line salvage chemotherapy is unclear. We evaluated the utility of further chemotherapy in pts unresponsive to GDP and to determine transplant outcomes of pts with stable disease (SD). Methods: This was a retrospective, single centre study of 118 pts from 2001–2008 with refractory/relapsed HL after ABVD or equivalent chemotherapy who were eligible for AHCT and received GDP as first line salvage chemotherapy. Patients undergoing AHCT had progenitor cells mobilized with cyclophosphamide (2g/m2 D1), etoposide (200mg/ m2 D1–3) and G-CSF. Intensive therapy consisted of etoposide 60mg/kg and melphalan 180mg/m2. Involved field radiation was given after AHCT to disease sites > 5cm. Response assessment prior to AHCT was performed using CT +/−gallium scan. Patients achieving PR or complete remission (CR) to GDP proceeded to AHCT. Pts with progressive disease (PD) on GDP were offered second line salvage chemotherapy with miniBEAM (MB; melphalan, etoposide, cytarabine, BCNU). Patients with SD post GDP were generally given further MB if residual mass was >5cm or if they remained gallium avid. Results: Median age was 38, (range 18–65), 42% were female, 80% had nodular sclerosis HL. At diagnosis, 21% had limited stage (1A/2A); 29% received radiotherapy. At relapse/ progression 36% had limited stage; 25% had B symptoms; 39% had primary refractory disease; median largest mass size was 4cm (range 1–12cm). Median follow up for transplanted (n=110) and non-transplanted (n=8) pts was 25.2 and 19 months, respectively. Response rate (PR+CR) to GDP chemotherapy was 75% (88/118). Response to GDP was unknown in 1 pt. 21 patients had SD and 8 had PD. 8 pts with SD post-GDP received MB resulting in 1 PR, 4 SD (1 gallium avid) and 3 PD. Eight pts with PD post-GDP received MB resulting in 4 PR, 1 SD (gallium avid) and 3 PD. Of the 16 MB pts, 8 responded adequately (PR or SD and gallium negative) and proceeded to AHCT. Median PFS for these 8 transplanted pts was 3.5 months (range 1–23), 2 year PFS was 23%. Of the 16 pts who received MB, only 3 (19%) remain in remission, 2 with less than 6 months follow up. We compared the disease characteristics (age, gender, mass size, stage, B symptoms, time to relapse) at first relapse/progression between the pts in SD transplanted after GDP alone to the 8 pts transplanted after MB. Patients receiving MB and AHCT were more likely to have B symptoms at relapse compared to pts with SD transplanted after GDP alone, p=0.048). For pts undergoing AHCT after GDP alone, 2 year PFS for those achieving PR/CR (n=88) to GDP compared to those only achieving SD (n=13) was similar − 69% for both groups (95%CI 59–81% for PR/CR and 48–99% for SD). No difference in disease characteristics at relapse was noted between the two groups. Conclusion: Selected patients (i.e. those with low bulk who are gallium negative) transplanted in SD after GDP have a comparable outcome to those transplanted in PR/CR. Patients who require additional therapy to achieve disease control prior to AHCT have a high relapse rate despite aggressive treatment. Additional studies evaluating functional imaging to direct further therapy and novel treatment strategies for pts with an inadequate response to chemotherapy pre-AHCT are warranted.

Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4549-4549
Author(s):  
L. Di Lauro ◽  
S. I. Fattoruso ◽  
L. Giacinti ◽  
P. Vici ◽  
D. Sergi ◽  
...  
Keyword(s):  
Distant Metastases ◽  
Metastatic Gastric Cancer ◽  
Second Line ◽  
First Line ◽  
Second Line Chemotherapy ◽  
First Line Therapy ◽  
Line Therapy ◽  
Previously Treated ◽  
Grade 3 ◽  
Line Chemotherapy

4549 Background: No established second-line chemotherapy exists for patients (pts) with MGC failing to respond or progressing after first-line chemotherapy. This study was designed to determine the efficacy and safety of FOLFIRI combination used as second-line therapy in pts with MGC not previously treated with regimens containing fluoropyrimidines. Methods: Pts with measurable distant metastases, previously treated with a combination of epirubicin, docetaxel and cisplatin or oxaliplatin as first-line therapy, received irinotecan 180 mg/mq (150 mg/mq in pts >70 ys old) as a 1-h infusion day 1; leucovorin 100 mg/mq/day followed by bolus fluorouracil (FU) 400 mg/mq and a 22-h infusion of FU 600 mg/mq day 1–2, every 2 weeks for a maximum of 12 cycles or until disease progression, unacceptable toxicity or patients refusal. Endpoints were response rate (RR), time to progression (TTP), overall survival (OS) and safety. Results: 38 pts were enrolled: M/F 23/15; median age 66 ys (34–75); median ECOG PS 1 (0–2); number of metastatic sites 1/2/≥3: 9/18/11 pts, respectively. A total of 223 cycles was performed (median 6, range 2–12). One CR and 8 PR were observed for an overall RR of 24% (95% CI, 11–39 %). Disease remained stable in 11 pts. Median TTP was 4.0 months (95% CI, 2.9–5.1) and median OS was 6.2 months (95% CI, 4.7–7.7). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 29%, 3% and 8% of pts, respectively. Febrile neutropenia was seen in 2 pts (5%). Other grade 3 toxicities included diarrhea in 5 pts (13%), mucositis in 2 pts (5%) and vomiting in 2 pts (5%). There were no treatment related deaths. Conclusions: FOLFIRI is an active and well tolerated second-line regimen for MGC pts not previously treated with fluoropyrimidines. No significant financial relationships to disclose.

Long-term second-line chemotherapy consisting of oral S-1 and gemcitabine for NSCLC: A phase II study—TORG 0705.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e18007-e18007
Author(s):  
Y. Takiguchi ◽  
T. Seto ◽  
Y. Ichinose ◽  
N. Nogami ◽  
H. Okamoto ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival

2003 ◽  
Vol 21 (4) ◽  
pp. 710-715 ◽  
Author(s):  
Stefano Ferrari ◽  
Antonio Briccoli ◽  
Mario Mercuri ◽  
Franco Bertoni ◽  
Piero Picci ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Lung Metastases ◽  
Pulmonary Nodules ◽  
Second Line ◽  
Chemotherapy Treatment ◽  
Term Survival ◽  
Second Line Chemotherapy ◽  
First Recurrence ◽  
Line Chemotherapy

Purpose: To identify factors that influence postrelapse survival (PRS) in patients with nonmetastatic osteosarcoma of the extremity Patients and Methods: One hundred sixty-two patients with recurrent osteosarcoma of the extremity were retrospectively reviewed. The first-line treatment included surgery of the primary lesion and chemotherapy with methotrexate, doxorubicin, cisplatin, and ifosfamide. Results: The projected 5-year PRS rate was 28%. Patients who had complete surgery of recurrence had a 5-year PRS of 39%, whereas for those who did not have complete surgery, PRS was 0% at 3 years (P < .0001). In the latter group, PRS was not influenced by site of recurrence and relapse-free interval (RFI), although it was influenced (P = .006) by the use of second-line chemotherapy (PRS, 53% at 12 months for patients who received chemotherapy v 12% for those who did not). In patients who had complete surgery, PRS was influenced by site of relapse (5-year PRS, lung 44%, other 19%; P < .06), RFI (5-year PRS at ≤ 24 months, 20%; at > 24 months, 60%; P < .0001), and number of lung metastases (5-year PRS, two or fewer nodules, 59%; more than two nodules, 14%; P < .0001) but not by the use of a second-line chemotherapy treatment. Conclusion: RFI, site of metastases, and number of pulmonary nodules are the main prognostic factors for PRS in osteosarcoma. Complete surgery of recurrence is pivotal in the strategy of treatment. Patients with unresectable recurrence benefit from second-line chemotherapy, whereas our data do not support a generalized use of chemotherapy after complete surgery of first recurrence.

Second-line chemotherapy in advanced gastric cancer: A retrospective, single-center analysis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15170-15170
Author(s):  
C. Herrmann ◽  
D. Jaeger ◽  
T. Herrmann
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Chemotherapy Regimen ◽  
Salvage Chemotherapy ◽  
Second Line ◽  
First Line ◽  
Second Line Chemotherapy ◽  
Third Line ◽  
Line Chemotherapy

15170 Background: The role of second-line chemotherapy in advanced gastric cancer is not yet established. We analyzed patients with advanced gastric cancer treated at our department between 2002 and 2005 comparing the outcome of patients with first-line chemotherapy only and those who received second-line chemotherapy. Patients and Methods: 51 patients with metastatic or recurrent histologically confirmed gastric cancer were analyzed in this retrospective study. The choice of chemotherapy depended on the attending physician. Results: Altogether, 17 patients (33.3 %) were treated with only one chemotherapy regimen, whereas 34 patients (66.6 %) received at least two different chemotherapy regimens. During the last years, the preference for certain chemotherapy regimens changed. At the time of analysis, 9 patients were still alive. Median overall survival was 11 months (range: 1–41). Patients who received only one chemotherapy regimen were older (median age 70, range: 47–81), had a shorter TTP (3.5 months, range: 1–15) and a shorter overall survival (6 months, range: 2–25) than patients receiving sequential chemotherapies (median age 61.5 (range: 33–79) p = 0,009, TTP under first-line therapy 5 months (1–17), p = 0,45, overall survival 14.5 months (2–41), p = 0,001). Response to second-line chemotherapy was assessed in 32 patients: Partial remission was detected in 4 patients (12.5 %), stable disease for = 3 months in 15 patients (46.8 %), whereas disease progression occurred in 12 patients (37.5 %). 10 of 51 patients (19.6 %) received more than two different treatments: 4 patients had third-line chemotherapy, 6 patients had more than 3 different therapies. Overall survival was 13 months (11–22) for patients with third-line chemotherapy and 29 months (16–41) for patients receiving more than three different treatment regimens. Conclusion: Although a number of active antineoplastic drugs are available for the treatment of advanced gastric cancer, the prognosis is still poor. Selected patients may benefit from salvage chemotherapy after failure of first-line chemotherapy. No significant financial relationships to disclose.

FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

2020 ◽  
Author(s):  
Angela Lamarca ◽  
Daniel Palmer ◽  
Harpreet Wasan ◽  
Paul J. Ross ◽  
Yuk Ting Ma ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Tract Cancer ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document